In a study from University Medical Center Groningen, scientists found that dapagliflozin— a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes—reduces the rate of kidney function decline in patients with chronic kidney disease (CKD).
In the study, the team examined 4,304 participants with CKD. They were assigned to dapagliflozin 10 mg or placebo once daily, added to standard care.
The researchers found although participants without diabetes also experienced a slower rate of kidney function decline with dapagliflozin, the effect of dapagliflozin was greater in those with diabetes.
The key conclusion is that dapagliflozin is an effective treatment to slow progressive kidney function loss in patients with CKD with and without type 2 diabetes.
Therefore, in addition to reducing the risk of heart failure or mortality, as previously shown in the DAPA-CKD trial, dapagliflozin also slows the progression of kidney function decline.
If you care about kidney health, please read studies about big causes of chronic kidney disease, and what you need to know about kidney disease and COVID-19.
For more information about kidney health, please see recent studies about how to protect your kidneys from diabetes, and results showing eating nuts linked to lower risk of chronic kidney disease and death.
The study was conducted by Hiddo Lambers Heerspink et al and presented at ASN Kidney Week.
Copyright © 2022 Knowridge Science Report. All rights reserved.
